Zhejiang Yatai Pharmaceutical: Being investigated by top securities regulator

NBD AI Bulletin,Zhejiang Yatai Pharmaceutical Co., Ltd. (the Company, SZ 002370, close: 4.76 yuan) announced on the evening of July 2 that it received a notice from China Securities Regulatory Commission (CSRC) on December 31, 2019, which says the Company is suspected of illegally disclosing information and the CSRC decided to launch an investigation into the matter.

As of the date of this announcement, the Company has not received concluding opinions or relevant progress documents on the above-mentioned investigation. If the Company is subject to administrative punishment by the CSRC for the above-mentioned investigation, the Company's stock will be subject to a de-listing risk warning.

According to the 2019 annual report, Zhejiang Yatai Pharmaceutical Co., Ltd. mainly engages in pharmaceutical manufacturing and services, accounting for 86.51% and 12.96% of its revenue, respectively.

Zhejiang Yatai Pharmaceutical Co., Ltd.'s general manager and chairman is Chen Yaogen, male, 69 years old, college degree, Chinese national, no permanent residence abroad, senior economist.

(By Tan Yuhan)

Disclaimer: This article is for informational purposes only and does Not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.